GLP3-RT 10mg

GLP3-RT (Retatrutide) is a synthetic research peptide engineered as a triple receptor agonist — simultaneously targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Each of these receptors sits at a distinct control point in mammalian metabolism, and combining activity across all three has become one of the most closely watched frontiers in incretin biology. Researchers are interested in this multi-receptor approach because single- and dual-agonist compounds have shown that engaging more than one incretin pathway can produce broader metabolic effects than either pathway alone. Adding glucagon-receptor activity introduces an additional lever on energy expenditure and hepatic lipid handling, which is why investigators view the triple-agonist profile as a distinct pharmacological class rather than a simple extension of prior peptides. Current investigational literature examines GLP3-RT across appetite regulation, energy expenditure, glucose homeostasis, insulin sensitivity, body composition, and cardiometabolic markers. It is studied strictly as a laboratory research compound to characterize receptor pharmacology, downstream signaling, and long-term metabolic adaptation in preclinical and clinical research settings.

• Published studies have investigated GLP3-RT as a triple agonist at the GLP-1, GIP, and glucagon receptors
• Research suggests combined incretin and glucagon activity may influence appetite signaling and energy intake more broadly than single-receptor agonists
• Current evidence indicates activity at the glucagon receptor is associated with increases in resting energy expenditure in preclinical models
• Investigators have observed effects on glycemic control and insulin sensitivity across metabolic research literature
• Published research has examined changes in body composition, including reductions in adiposity, in animal and clinical study cohorts
• Research suggests potential effects on hepatic lipid metabolism, an area of active cardiometabolic investigation
• Investigators continue to characterize downstream signaling of the triple-receptor mechanism at the cellular level
• Current evidence indicates long-term metabolic adaptation to multi-receptor agonism remains an open area of ongoing study

• Appetite regulation research
• Body weight and body composition studies
• Energy expenditure investigation
• Glucose metabolism research
• Insulin sensitivity studies
• Metabolic flexibility investigation
• Cardiometabolic health research
• Long-term metabolic adaptation studies

• Lyophilized — requires reconstitution with BAC water
• Store refrigerated at 36–46°F (2–8°C)
• Research use only — not for human consumption